208 related articles for article (PubMed ID: 24563017)
1. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study.
Zdarska DJ; Kvapil M; Rusavy Z; Krcma M; Broz J; Krivska B; Kadlecova P
Wien Klin Wochenschr; 2014 Apr; 126(7-8):228-37. PubMed ID: 24563017
[TBL] [Abstract][Full Text] [Related]
2. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
3. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
5. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche A; Schweitzer MA; Häring HU;
Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system.
Wang XL; Lu JM; Pan CY; Mu YM; Dou JT; Ba JM; Wang X
Diabetes Res Clin Pract; 2007 Apr; 76(1):30-6. PubMed ID: 16979255
[TBL] [Abstract][Full Text] [Related]
7. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
8. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
9. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy.
Zick R; Petersen B; Richter M; Haug C;
Diabetes Technol Ther; 2007 Dec; 9(6):483-92. PubMed ID: 18034602
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
[TBL] [Abstract][Full Text] [Related]
11. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
12. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
[TBL] [Abstract][Full Text] [Related]
13. Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain.
Delgado E;
Int J Clin Pract; 2012 Mar; 66(3):281-8. PubMed ID: 22340448
[TBL] [Abstract][Full Text] [Related]
14. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
15. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
[TBL] [Abstract][Full Text] [Related]
16. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
Hershon KS; Blevins TC; Mayo CA; Rosskamp R
Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
[TBL] [Abstract][Full Text] [Related]
17. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.
Porcellati F; Lin J; Lucidi P; Bolli GB; Fanelli CG
Medicine (Baltimore); 2017 Feb; 96(5):e6022. PubMed ID: 28151905
[TBL] [Abstract][Full Text] [Related]
18. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
19. Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy.
Bellia A; Babini AC; Marchetto PE; Arsenio L; Lauro D; Lauro R
Acta Diabetol; 2014 Apr; 51(2):269-75. PubMed ID: 24275956
[TBL] [Abstract][Full Text] [Related]
20. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
